OSAWELL

In the field of Obstructive Sleep Apnea (OSA), Shell Biotech has entered the rapidly growing global market of Dental Sleep Medicine through its proprietary brand, OSAWELL. As aging populations, chronic sleep disorders, and the demand for interdisciplinary healthcare integration continue to rise, next-generation Oral Appliance Therapy (OAT) has become a critical treatment gateway connecting dentistry, sleep medicine, and digital healthcare — offering strong clinical demand and significant scalability potential.
 

Shell Biotech has pioneered an innovative system integrating 3D imaging and an AI-driven treatment design engine, transforming conventional mandibular advancement device (MAD) therapy from a simple forward-positioning approach into a comprehensive 3D spatial treatment concept. The company has also invested extensively in research focused on temporomandibular joint (TMJ) asymmetric occlusal movement and dental sleep medicine.

Supported by a QMS-compliant medical manufacturing system, Shell Biotech empowers clinicians to deliver highly precise, predictable, and reproducible sleep treatment solutions. Through long-term academic collaborations with leading medical universities in Taiwan and around the world, the company continues to accumulate clinical data and establish standardized treatment protocols, further strengthening trust and credibility within the industry.